NCT06299748View on ClinicalTrials.gov

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy And/or Breastfeeding.

RecruitingOBSERVATIONAL
Enrollment

279

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

January 31, 2033

Study Completion Date

December 31, 2033

Conditions
Myasthenia GravisCIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
BIOLOGICAL

Efgartigimod

Efgartigimod IV or SC

Trial Locations (1)

26508

RECRUITING

United BioSource LLC, Morgantown

Sponsors

Lead Sponsor

argenx
All Listed Sponsors
lead

argenx

INDUSTRY

NCT06299748 - A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy And/or Breastfeeding. | Biotech Hunter | Biotech Hunter